NCT02738489View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 13, 2016

Primary Completion Date

January 8, 2020

Study Completion Date

January 8, 2020

Conditions
Advanced Melanoma
Interventions
BIOLOGICAL

SHR-1210

A fully human monoclonal immunoglobulin (IgG4 subtype)

Trial Locations (1)

Unknown

Cancer Hospital Affiliated to Beijing University, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT02738489 - A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma | Biotech Hunter | Biotech Hunter